Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Paclitaxel, Gemcitabine and Cisplatin in Relapsing Germ Cell Cancer After First-line Chemotherapy
2007-000618-35Phase 2Active
- Sponsor
- Rigshospitalet
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, gemcitabine and paclitaxel in germ cell tumor (GCT), Germ Cell Testicular Cancer, seminoma and 1 more, sponsored by Rigshospitalet. Primary endpoint: Progression-free survival. Started Aug 2007; status: active.
02
Drugs
cisplatingemcitabinepaclitaxel
03
Conditions
germ cell tumor (GCT)Germ Cell Testicular CancerseminomaNon-Germinomatous Germ Cell Tumor (NGGCT)
Beyond the preview
Go deeper on 2007-000618-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000618-35.